Ka la 25 Mmesa, 2025, InnoCare Pharma e phatlalalitse hore moloko oa eona o mocha oa pan-TRK inhibitor zurletrectinib (ICP-723) o filoe tlhahlobo ea pele ke Setsi sa Tlhahlobo ea Meriana (CDE) sa Tsamaiso ea Lihlahisoa tsa Bongaka ea Naha ea Chaena (NMPA), se amohetseng Kopo e Ncha ea Meriana (NDA) ea zurletrectinib bakeng sa kalafo ea bakuli ba nang le lihlahala tse matla tse tsoetseng pele tse nang le li-gene fusions tsa NTRK haufinyane. Tlhahlobo ea bohlokoa ke e 'ngoe ea maano a bohlokoa a hlahisitsoeng ke CDE ho potlakisa tumello ea meriana.
Tekong ea ngoliso bakeng sa bakuli ba nang le lihlahala tse tiileng tsa NTRK fusion-positive, zurletrectinib e bontšitse katleho e ikhethang ka boemo bo botle ba polokeho.
Ngaka Jasmine Cui, mothehi-'moho, modulasetulo le CEO oa InnoCare, o itse, "Re thabetse hore zurletrectinib e filoe tlhahlobo ea pele. Zurletrectinib e bontšitse katleho e ikhethang le boemo bo botle ba polokeho. Re lebeletse hore e tla fana ka likhetho tse betere tsa kalafo bakeng sa bakuli ba tšoanelehang ba nang le lihlahala tse tiileng pejana."
Zurletrectinib ke thibelo ea pan-TRK e ntlafalitsoeng ke InnoCare. British Journal of Cancer, karolo ea koranta e etellang pele ea saense Nature, e phatlalalitse pampiri e nang le sehlooho se reng "Zurletrectinib ke thibelo ea TRK ea moloko o latelang e nang le ts'ebetso e matla ea ka hare ho boko khahlanong le lihlahala tse nang le NTRK tse nang le khanyetso e tobileng ho li-agent tsa moloko oa pele".
Pampiri e bontšitse hore zurletrectinib e bontšitse matla a maholo khahlanong le TRKA, TRKB, le TRKC WT kinases, hammoho le liphetoho tse fumanoeng tsa khanyetso ea TRKA G595R le TRKA G667C. Zurletrectinib e ne e le mafolofolo ho feta meloko e meng ea pele e amohetsoeng ke FDA kapa e lekiloeng ke lingaka (larotrectinib) le moloko o latelang (selitrectinib le repotrectinib) ea li-TRK inhibitors khahlanong le liphetoho tse ngata tsa khanyetso ea li-TRK inhibitors. Ka mokhoa o ts'oanang, zurletrectinib (1 mg/kg BID) e thibetse kholo ea hlahala mefuteng ea xenograft e nkiloeng liseleng tse nang le NTRK fusion-positive ka tekanyo e tlase ka makhetlo a 30 ha e bapisoa le selitrectinib.
Pampiri ena e boetse e bontšitse hore, thutong ea meriana ea tsamaiso ea methapo ea kutlo (CNS) e kenang litoebeng tsa SD, zurletrectinib e bontšitse bokhoni bo ntlafetseng ba ho kenella mokoallong oa mali le boko, e fihla bokong ka katleho ho feta selitrectinib le repotrectinib. Ho kenella ho eketsehileng ha boko ba Zurletrectinib ho ile ha boela ha fetoleloa tšebetsong e ntlafetseng ea ho loantša hlahala. Mohlaleng oa xenograft oa toeba ea orthotopic glioma o jereng phetoho ea khanyetso ea TRKA G598R/G670A, zurletrectinib (15 mg/kg) e ntlafalitse haholo ho phela ha litoeba tse nang le orthotopic NTRK fusion-positive, TRK-mutant gliomas (medium survival = 41.5, 66.5, le matsatsi a 104 bakeng sa selitrectinib, repotrectinib, le zurletrectinib ka ho latellana; P < 0.05), e bonts'ang katleho e phahameng ha e bapisoa le repotrectinib (15 mg/kg) le selitrectinib (30 mg/kg) (P=0.0384 le 0.0022, ka ho latellana), ka boemo bo botle ba polokeho.
Lijini tsa NTRK fusion li hlaha mefuteng e fapaneng ea lihlahala tsa batho ba baholo le tsa bana. Lihlahalang tse ling tse sa tloaelehang, tse kang carcinoma ea litšoelesa tsa mathe, kankere ea matsoele e ntšang secretory, le fibrosarcoma ea masea, palo ea lihlahala tsa NTRK gene fusion e feta 90%. Ho hakanngoa hore ho na le linyeoe tse ncha tse ka bang 6,500 tsa lihlahala tse tiileng tsa NTRK fusion-positive tse fumanoang Chaena selemo se seng le se seng. Ho na le litlhoko tse kholo tsa kliniki tse sa fihlelleheng sebakeng sena ka lebaka la khaello ea mekhoa e sebetsang ea kalafo.
Hona jwale, ho ntse ho na le diteko tse ngata tsa bongaka tsa mahlale a matjha a ho lwantsha kankere Chaena a batlang bakudi. Dipuisano mabapi le meriana le mahlale a matjha, o ka ikopanya le Lefapha la Matjhaba la Sepetlele sa Oncology sa Beijing Region South.
Nomoro ea mohala: 4008803716
Email：myimmnet@163.com
Nako ea poso: Mots'eanong-07-2025